BREAST CANCER TRIPLE NEGATIVE
Clinical trials for BREAST CANCER TRIPLE NEGATIVE explained in plain language.
Never miss a new study
Get alerted when new BREAST CANCER TRIPLE NEGATIVE trials appear
Sign up with your email to follow new studies for BREAST CANCER TRIPLE NEGATIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple threat: radiation and immunotherapy before chemotherapy may boost breast cancer response
Disease control Recruiting nowThis phase 2 trial is testing whether giving a short course of radiation (SBRT) and two injections of the immunotherapy drug pembrolizumab (Keytruda) before standard chemotherapy can improve outcomes for people with stage 2 or 3 breast cancer. The study aims to see if this combin…
Matched conditions: BREAST CANCER TRIPLE NEGATIVE
Phase: PHASE2 • Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Small study aims to predict which breast cancer patients benefit from immunotherapy
Knowledge-focused Recruiting nowThis pilot study is looking at how the immune system responds in people with early-stage triple negative breast cancer who receive standard chemotherapy plus the immunotherapy drug pembrolizumab before surgery. The goal is to see if certain immune markers in the blood or tumor ti…
Matched conditions: BREAST CANCER TRIPLE NEGATIVE
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC